# Forensic Dossier: Study Forensics: Gene therapy elevating Klotho protein extends lifespan in mice

**Run ID:** `full27_study-forensics-024_Claude_Haiku_d285a1`  
**Task:** study-forensics-024 | study_forensics | hard | study_forensics  
**Timestamp:** 2026-04-08T17:01:07.047691+00:00  
**Task Family:** mechanism_vs_evidence  
**Trap Type:** animal_to_human_overreach  
**Ambiguity:** low  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **74.2/100** (margin: 0.0)
**Failure modes:** missed_key_insight, unsupported_conclusion, unsupported_intermediate_step
**Forensic flags:** 3
**Consistency findings:** 5
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 30.0/30 | 0.0/8 | 4.8/8 | 3.9/6 | 3.9/6 | 5.5/6 | 5.6/8 | 8.0/8 | 4.0/10 | 8.5/10 | **74.2/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `mechanism_vs_evidence` [+] (gold: `mechanism_vs_evidence`)
**Finding Recall:** 67%
**Matched Findings:** mechanism_not_demonstrated, conclusion_exceeds_results
**Missed Findings:** unsupported_generalization
**Extra Findings:** cautious_scope_control, none_or_minor, decorative_uncertainty, correlation_as_causation

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct but brittle reasoning
**Load-bearing steps:** 0 / 7

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :white_check_mark: effect |
| Mechanism described | :white_check_mark: (1 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "mechanism_vs_evidence"


## Forensic Flags

### Claude Haiku

- **[MAJOR]** `unsupported_leap`: Correct answer with weak support chain — final answer may be an unsupported leap
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "mechanism_vs_evidence"
- **[MODERATE]** `ungrounded_mechanism`: Mechanism named/described but not connected to case-specific data
  - `(mechanism analysis)`: "effect"


## Evidence Map

### Claude Haiku

**Correctness:** 30.0/30
  - (+) `final_answer`: "mechanism_vs_evidence"
    _Agent's answer for correctness check_
  - Note: Exact match

**Support Strength:** 0.0/8
  - (-) `final_answer`: "mechanism_vs_evidence"
    _Conclusion not supported by steps_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 7
  - Note: Reasoning graph: conclusion not well grounded

**Structural Reasoning:** 4.8/8
  - (+) `steps[1]`: "2. CONCLUSION TIER IDENTIFICATION: The text explicitly suggests therapeutic application in humans ('with a suitable deli"
    _Most informative reasoning step_
  - Note: 7 reasoning steps
  - Note: Low step utility: 0/7 steps contribute

**Assumption Discipline:** 3.9/6
  - (+) `assumptions[2]`: "Outcomes measured include lifespan extension (15-20%), muscle strength, bone density, cognitive performance, neurogenesi"
    _Most substantive assumption_
  - Note: 5/5 substantive assumptions

**Uncertainty Handling:** 3.9/6
  - (+) `uncertainties[0]`: "Whether the mouse lifespan extension was measured to natural death or censored at a fixed age (affects interpretation of"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.88"
    _Stated confidence level_
  - Note: 5 uncertainties (5 substantive)
  - Note: Confidence 0.88

**Alternative Hypothesis Quality:** 5.5/6
  - (+) `alternative_hypotheses[0]`: "solid: If the study included human pilot data or phase 1 trials alongside the mouse work, and the text simply emphasized"
    _Most substantive alternative hypothesis_
  - Note: 3 alternative hypotheses considered
  - Note: 2/3 include rejection reasoning

**Self Monitoring Quality:** 5.6/8
  - (+) `self_check[0]`: "Did I overclassify? No. The text explicitly suggests human therapeutic application ('could help build a healthier societ"
    _Most substantive self-verification step_
  - Note: 5 self-check items
  - Note: Self-check quality: 0 deep, 5 arithmetic, 0 fluff

**Mechanism Quality:** 4.0/10
  - (+) `(mechanism analysis)`: "5. MECHANISM VS. EVIDENCE CHECK: The text describes a plausible biological mechanism (Klotho production → neurogenesis, "
    _Mechanism description without case grounding_
  - Note: Names concept + describes mechanism (not grounded to case)

**Communication Efficiency:** 8.5/10
  - Note: Signal density: 0.71, 670 words

**Insight Depth:** 8.0/8
  - (+) `(output text)`: "vector gene therapy. this is animal model research (tier 2). 2. conclus"
    _Insight 'animal model' matched (exact)_
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Haiku

**MODERATE:**
- **Unsupported Conclusion** `[MEDIUM CONFIDENCE]`: Final answer lacks load-bearing or supporting step grounding
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: support_strength_
- **Unsupported Intermediate Step** `[MEDIUM CONFIDENCE]`: No reasoning step is load-bearing — final answer lacks traceable derivation
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: support_strength, structural_reasoning_
- **Missed Key Insight** `[MEDIUM CONFIDENCE]`: Missed expected finding: unsupported_generalization
  - `(task expectation)`: "Expected: unsupported_generalization"
  - _Impacts: insight_depth_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (1/19 content words)
  - `key_claims[0]`: "MAIN EPISTEMIC ISSUE: The text bridges from animal evidence (Tier 2) to human therapeutic implicatio"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (1/13 content words)
  - `key_claims[1]`: "SECONDARY ISSUE: The mechanism (Klotho → neurogenesis, immune activity) is plausible but demonstrate"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/15 content words)
  - `key_claims[2]`: "STRENGTH: The study appears well-designed (viral vector, multiple outcome measures, lifespan extensi"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (1/9 content words)
  - `key_claims[3]`: "PATENT FILINGS: Suggest commercial interest but are not evidence of efficacy or safety in humans."
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 2 is stated without rejection reasoning
  - `alternative_hypotheses[1]`: "overclaim: If the text made stronger claims about human benefit without any hedging. (The text does "


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 16071ms

**Final Answer:** mechanism_vs_evidence

**Confidence:** 0.88

**Assumptions:**
- The study was conducted in mice (middle-aged, not aged to death)
- The intervention was a viral vector gene therapy delivering secreted Klotho
- Outcomes measured include lifespan extension (15-20%), muscle strength, bone density, cognitive performance, neurogenesis, and immune markers
- No human trials are mentioned or implied to have been conducted
- The text presents this as a preclinical finding with future therapeutic potential

**Reasoning Steps:**
1. 1. EVIDENCE TIER IDENTIFICATION: The study is conducted in mice using viral vector gene therapy. This is animal model research (Tier 2).
2. 2. CONCLUSION TIER IDENTIFICATION: The text explicitly suggests therapeutic application in humans ('with a suitable delivery method, this gene therapy could help build a healthier society by combating age-related decline') and mentions patent filings for treating human conditions (bone, muscle, aging-related deficits).
3. 3. BRIDGE GAP DETECTION: There is a substantial gap between animal model evidence and implied human therapeutic benefit.
4. 4. HEDGE ANALYSIS: The text uses cautious language ('could help,' 'with a suitable delivery method,' 'suggested that') which acknowledges uncertainty but does not close the evidence gap. These hedges are decorative—they acknowledge the gap exists but do not provide evidence that bridges it.
5. 5. MECHANISM VS. EVIDENCE CHECK: The text describes a plausible biological mechanism (Klotho production → neurogenesis, immune activity, physiological improvements) but this mechanism is demonstrated only in mice. Translating lifespan extension, muscle strength, bone density, and cognitive gains from mice to humans requires evidence not present in this summary.
6. 6. CONFOUNDERS NOT ADDRESSED: No mention of control groups, dose-response relationships, potential off-target effects of viral vectors, or whether improvements are specific to Klotho or general effects of gene therapy.
7. 7. PATENT FILING AS SIGNAL: Patent filings indicate commercial intent but do not constitute evidence of human efficacy or safety.

**Key Claims:**
- MAIN EPISTEMIC ISSUE: The text bridges from animal evidence (Tier 2) to human therapeutic implication (Tier 5) without direct human evidence. Hedging language acknowledges this gap but does not eliminate it.
- SECONDARY ISSUE: The mechanism (Klotho → neurogenesis, immune activity) is plausible but demonstrated only in mice. Generalization to humans is speculative.
- STRENGTH: The study appears well-designed (viral vector, multiple outcome measures, lifespan extension), but this does not resolve the animal-to-human translation gap.
- PATENT FILINGS: Suggest commercial interest but are not evidence of efficacy or safety in humans.

**Alternative Hypotheses:**
- solid: If the study included human pilot data or phase 1 trials alongside the mouse work, and the text simply emphasized the mouse findings. (Not supported by the text provided.)
- overclaim: If the text made stronger claims about human benefit without any hedging. (The text does hedge, so mechanism_vs_evidence is more precise than overclaim.)
- correlation_vs_causation: If the study were observational in humans. (The study is experimental in mice, so this does not apply.)

**Uncertainties:**
- Whether the mouse lifespan extension was measured to natural death or censored at a fixed age (affects interpretation of the 15-20% figure)
- Whether the cognitive and muscle improvements are direct effects of Klotho or secondary to systemic health improvements
- Whether the viral vector delivery method used in mice is feasible or safe in humans
- Whether the patent filings indicate active human development or are speculative
- The specific age of the 'middle-aged' mice and whether this is a good model for human aging

**Self-Verification:**
- Did I overclassify? No. The text explicitly suggests human therapeutic application ('could help build a healthier society'), which is a human_therapeutic conclusion tier. The evidence is animal-only. This is a genuine mechanism_vs_evidence issue, not a false positive.
- Did I miss a bridge? The text provides no human data, no phase 1 trials, no biomarker studies in humans. The bridge is absent.
- Is the hedging sufficient? No. Hedging language ('could,' 'with suitable delivery') acknowledges uncertainty but does not provide evidence. This is decorative uncertainty.
- Did I conflate overclaim with mechanism_vs_evidence? Correctly distinguished: the text is not claiming certainty (so not overclaim), but it is implying human benefit from animal evidence (mechanism_vs_evidence).
- Is the study itself flawed or just the reporting? The study appears sound (animal model, multiple outcomes, lifespan extension). The issue is the leap from mice to humans in the summary/framing.

**Dimension Scores:**
- Correctness: 30.0/30 `##########`
- Support Strength: 0.0/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 3.9/6 `######....`
- Uncertainty Handling: 3.9/6 `######....`
- Alternative Hypothesis Quality: 5.5/6 `#########.`
- Self Monitoring Quality: 5.6/8 `#######...`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 4.0/10 `####......`
- Communication Efficiency: 8.5/10 `########..`


## Final Verdict

**Solo run: Claude Haiku** scored **74.2/100**.

**Best per dimension:**
- Correctness: Claude Haiku (30.0/30)
- Support Strength: Claude Haiku (0.0/8)
- Structural Reasoning: Claude Haiku (4.8/8)
- Assumption Discipline: Claude Haiku (3.9/6)
- Uncertainty Handling: Claude Haiku (3.9/6)
- Alternative Hypothesis Quality: Claude Haiku (5.5/6)
- Self Monitoring Quality: Claude Haiku (5.6/8)
- Insight Depth: Claude Haiku (8.0/8)
- Mechanism Quality: Claude Haiku (4.0/10)
- Communication Efficiency: Claude Haiku (8.5/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 16.1s | 74.2/100 | 4.6 |

Failure modes observed: missed_key_insight, unsupported_conclusion, unsupported_intermediate_step.
